Literature DB >> 18765704

Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005.

Aaron S Kesselheim1, David M Studdert.   

Abstract

Federal regulators have aggressively prosecuted health care fraud since the early 1990s, leading to billions of dollars in financial recoveries. Nearly all major cases today are qui tam actions, involving whistleblowers with inside knowledge of the allegedly illegal schemes. This article documents the outcomes of major enforcement actions and describe the schemes, defendants, and whistleblowers involved. The authors obtained an inventory of unsealed federal qui tam litigation targeting health care fraud that was resolved between 1996 and 2005 from the U.S. Department of Justice and gathered further information from publicly available sources. Among 379 cases, $9.3 billion was recovered, with more than $1.0 billion paid to whistleblowers. Case frequency peaked in 2001, but annual recoveries increased sharply from 2002 to 2005. Whistleblowers were frequently executives or physicians, and 75% were employees of defendant organizations. The 13 (4%) cases against pharmaceutical companies accounted for $3.6 billion (39%) of total recoveries. This study illuminates the scope and characteristics of qui tam fraud litigation and the whistleblowers who animate this important tool for addressing waste in the health care sector.

Mesh:

Year:  2008        PMID: 18765704     DOI: 10.7326/0003-4819-149-5-200809020-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  Why Not Blow the Whistle on Health Care Insurance Fraud? Evidence from Jiangsu Province, China.

Authors:  Dandan Wang; Changchun Zhan
Journal:  Risk Manag Healthc Policy       Date:  2022-10-12

2.  Conflict of interest reporting by authors involved in promotion of off-label drug use: an analysis of journal disclosures.

Authors:  Aaron S Kesselheim; Bo Wang; David M Studdert; Jerry Avorn
Journal:  PLoS Med       Date:  2012-08-07       Impact factor: 11.069

3.  Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints.

Authors:  Aaron S Kesselheim; Michelle M Mello; David M Studdert
Journal:  PLoS Med       Date:  2011-04-05       Impact factor: 11.069

4.  Challenging medical ghostwriting in US courts.

Authors:  Xavier Bosch; Bijan Esfandiari; Leemon McHenry
Journal:  PLoS Med       Date:  2012-01-24       Impact factor: 11.069

Review 5.  A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan.

Authors:  Tetsuya Tanimoto
Journal:  Drug Des Devel Ther       Date:  2015-03-31       Impact factor: 4.162

6.  The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.

Authors:  Bo Wang; David M Studdert; Ameet Sarpatwari; Jessica M Franklin; Joan Landon; Aaron S Kesselheim
Journal:  PLoS One       Date:  2017-04-07       Impact factor: 3.240

7.  Combating Health Care Fraud and Abuse: Conceptualization and Prototyping Study of a Blockchain Antifraud Framework.

Authors:  Tim Ken Mackey; Ken Miyachi; Danny Fung; Samson Qian; James Short
Journal:  J Med Internet Res       Date:  2020-09-10       Impact factor: 5.428

8.  Who is More Likely to Report Medical Insurance Fraud in the Two Scenarios of Whether It Results in a Direct Loss of Individual Benefit? A Cross-Sectional Survey in China.

Authors:  Hongyu Zhang; Ting Zhang; Qi Shi; Guomei Tian; Jian Liu; Jinpeng Xu; Bokai Zhang; Haixin Wang; Qunhong Wu; Zheng Kang
Journal:  Psychol Res Behav Manag       Date:  2022-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.